Decreased expression of C-MYC, however, was only observed upon single-use of ATO, which is in line with reports that showed C-MYC down-regulation after ATO treatment of mantle cell lymphoma and lung cancer cells (45, 46). This evidence concerns the gene MYC and lung cancer.